Abstract 3697
Background
Pancreatic neuroendocrine tumor (pNET) is rare and heterogeneous. New biomarkers are needed for better predicting the prognosis and providing individualized treatment. Versican (VCAN) plays an important role in tumorigenesis. Our previous study showed VCAN was specifically expressed in pNET tumor tissue. Therefore, we planned to investigate the role of VCAN in pNET prognosis.
Methods
Clinical and pathological data of pNET patients who underwent surgery between 2005 and 2010 were followed up and evaluated. VCAN expression was assessed by immunohistochemical (IHC) methods, and the relationship between VCAN and prognostic features of pNET was analyzed.
Results
Among 161 pNET patients, 118 (73.3%) pNET were VCAN expression positive and 43 (26.7%) VCAN expression negative. Positive expression of VCAN in pNET was significantly associated with longer disease-free survival (DFS) compared with VCAN-negative pNET (p = 0.017, HR 0.399, 95%CI 0.215-0.741). Subgroup analysis showed that VCAN-positive expression was associated with longer DFS in the G1 subgroup (p = 0.030, HR = 0.122, 95%CI: 0.013-1.180), tumor size>2cm subgroup (p = 0.030, HR = 0.427, 95%CI: 0.193-0.944) and NF-pNET subgroup (p = 0.001, HR = 0.251, 95%CI: 0.103-0.617). Multiple analysis showed that VCAN-negative expression, G2 and tumor size>2cm were independent factors for poor prognosis in pNET (p = 0.01, p < 0.001, p = 0.009, respectively).
Conclusions
Our data indicate that VCAN-positive expression may serve as an independent factor for predicting DFS prognosis in pNET. VCAN-positive expression in pNET tissues was correlated with longer DFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3240 - Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): an analysis of the TAGS study
Presenter: Maria Alsina
Session: Poster Display session 2
Resources:
Abstract
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract